Justin Klee ’13 and Joshua Cohen ’14, cofounders and co-CEOs of Amylyx Pharmaceuticals, received news that the U.S. Food and Drug Administration has approved Amylyx’s drug for slowing the progression of ALS, reversing its earlier decision after an outside panel of advisers recommended approval based on new data analysis. The drug, now branded as Relyvrio, was approved for the treatment of ALS in adults, as reported by Nasdaq.
See more notes:
Class of 2013